ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors
<i>ARAF</i> amplification was identified in 5-8% of EGFR-TKI-resistant tumors. The possible roles of ARAF in SCLC transformation warrant further investigation.
Authors
- Yuta Adachi (ORCID: https://orcid.org/0000-0003-1745-5039)
- Shogo Yanase
- Kentaro Hirade (ORCID: https://orcid.org/0000-0003-3606-7250)
- Ryo Kimura (ORCID: https://orcid.org/0000-0003-3220-991X)
- Makoto Ishii (ORCID: https://orcid.org/0000-0003-4396-1664)
- Yasuko Fujita (ORCID: https://orcid.org/0000-0002-3988-9076)
- Yutaka Fujiwara (ORCID: https://orcid.org/0000-0001-6981-0800)
- Satoru Kisoda
- Norio Shibata (ORCID: https://orcid.org/0000-0002-3742-4064)
- Rui Yamaguchi (ORCID: https://orcid.org/0000-0003-1224-227X)
- Hiromichi Ebi (ORCID: https://orcid.org/0000-0003-3155-7576)
- Waki Hosoda (ORCID: https://orcid.org/0000-0002-3288-8409)
Institutions
- Aichi Cancer Center (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3390/cancers16203501
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Merck KGaA
- Taiho Pharmaceutical
- Boehringer Ingelheim Japan
- Incyte
- Kyorin Pharmaceutical
- Moderna
- Insmed
- Daiichi-Sankyo
- Astellas Pharma
- Shionogi
- Otsuka Pharmaceutical
- Princess Takamatsu Cancer Research Fund
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe